share_log

科兴制药(688136.SH):注射用紫杉醇(白蛋白结合型)获得英国上市许可

Kexing Biopharm (688136.SH): Paclitaxel for Injection (Albumin Bound) obtains marketing authorization in the United Kingdom.

Gelonghui Finance ·  Oct 17 03:54

On October 17, Kexing Biopharm (688136.SH) announced that its partner Zhejiang Haichang Biomedical Technology Co., Ltd. recently received approval from the United Kingdom Medicines and Healthcare Products Regulatory Agency for the company's introduction of the injectable paclitaxel (albumin-bound) (Apexelsin, referred to as "albumin paclitaxel") market authorization.

The injectable paclitaxel (albumin-bound) formulation has clinical advantages over conventional paclitaxel injections and paclitaxel liposomes, with improved safety and patient compliance. It has high clinical acceptance and plays an indispensable clinical role in the field of cancer treatment.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment